Sera Prognostics was founded to develop diagnostic tests for the early prediction of a woman’s individualized risk of premature birth, preeclampsia, and other pregnancy complications. Sera’s tests are designed to give women and their physicians the power and time to make a difference in maternal and newborn health with individualized treatment and care plans. The company has completed enrollment and is in the validation phase for the landmark Proteomic Assessment of Preterm Risk (PAPR) clinical study. PAPR is an all-comer study representative of pregnant women in the U.S. It is the largest study of its kind and includes 5,501 women. The company’s proteomic predictor of premature birth risk—the PreTRM® Test for Risk Management-became commercially available in the U.S. in early 2016. VISION: EARLY PREDICTION OF PREMATURE BIRTH, PREECLAMPSIA, AND OTHER PREGNANCY COMPLICATIONS To be a global leader in high-value women’s health diagnostics, delivering pivotal information to patients and physicians that will improve the health of pregnant women and newborns and simultaneously improve the economics of healthcare.
Show more
Salt Lake City, US
Size (employees)
58 (est)+2%
Sera Prognostics was founded in 2008 and is headquartered in Salt Lake City, US
Report incorrect company information

Key People/Management at Sera Prognostics

Gregory C. Critchfield

Gregory C. Critchfield

Chairman & CEO
Andrew A. Sauter

Andrew A. Sauter


Sera Prognostics Office Locations

Sera Prognostics has an office in Salt Lake City
Salt Lake City, US (HQ)
200 2749 E Parleys Way
Show all (1)
Report incorrect company information

Sera Prognostics Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$69.6 m

Latest funding size

$20 m

Time since last funding

3 years ago


Sera Prognostics's latest funding round in January 2015 was reported to be $20 m. In total, Sera Prognostics has raised $69.6 m
Show all financial metrics
Report incorrect company information